Patients with metastatic anal cancer more frequently have abnormally high serum CEA levels relative to patients with newly diagnosed nonmetastatic disease or without evidence of disease following completion of chemoradiation. The gene discussed is CEACAM5; the disease is glycogen storage disease VI.